Show Podcast Information

Eroom’s Law is Moore’s Law spelled backwards. It’s a term that was coined in a Nature Reviews Drug Discovery article by researchers at Sanford Bernstein and describes the exponential decrease in biopharma research and development efficiency between the 1950s and 2010. Whereas Moore’s describes technologies becoming exponentially faster and cheaper over time, Eroom’s Law describes the trend of drug development becoming exponentially more expensive over time.

The article describing Eroom’s Law was published in 2012, and analyzed data up till 2010. That is perhaps ironic as 2010 appears to be an inflection point in the trend. In Breaking Eroom’s Law, the authors analyze the data since 2010 and show that costs appear to have stabilized over the last ten years. But what has contributed to this critical and exciting trend shift? In our conversation, Jorge and Vijay discuss the three causes cited by the authors of the Breaking Eroom’s Law article, their views on what technologies and policies will continue to push costs down, and their opinion on whether Eroom’s Law is broken for good.

Show Podcast Information

The COVID-19 pandemic has increased the visibility of scientists and the scientific process to the broader public; suddenly, scientists working on virology and infectious disease dynamics have seen their public profiles rapidly expand. One such scientist is the special guest in this episode, Trevor Bedford, Associate Professor at the Fred Hutchinson Cancer Research Center.

An expert in genomic epidemiology, he and his collaborators built Nextstrain, which shares real-time, interactive data visualizations to track the spread of viruses through populations.

a16z bio deal team partner Judy Savitskaya and Lauren Richardson chat with Trevor about how genomic epidemiology can inform public health decisions; viral mutation and spillover from animals into humans; what can be done now to prevent the next big pandemic; and the shift in scientific communication to pre-prints and open science.

Show Podcast Information

In this episode of the a16z bio journal club, we cover one of the key clinical trials that supported the recent FDA approval of the first prescription video game. The game was developed by Akili Interactive, is called EndeavorRx, and is now a clinically-validated therapy for improving attention in children with Attention Deficit Hyperactivity Disorder (ADHD). 

But how does a game improve attention? How does a clinical trial evaluate the efficacy of a game? And what are the pros and cons of a video game as compared to traditional pharmacological therapies for ADHD? Bio deal team partner Justin Larkin and Lauren Richardson delve into these questions and more in their discussion of this clinical trial:

“A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial” in Lancet Digital Health (April 2020) by Scott H Kollins, Denton J DeLoss, Elena Cañadas, Jacqueline Lutz, Robert L Findling, Richard S E Keefe, Jeffery N Epstein, Andrew J Cutler, and Stephen V Faraone.

a16z bio Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature — what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.

Show Podcast Information

As more digital natives have entered the workplace, they have brought with them the expectation that their software should both be a joy to use and allow them to be power users. That is, users who configure and control it to better serves their needs. And often, these digital natives aren’t just aspiring power users, they are also prosumers, who can and will pay for a premium experience. But first generation SaaS products have often struggled to deliver the experience these users crave.

For today’s founders and builders, how do you get the user experience right when a product has to delight your power users, while being something a less savvy user can pick up and learn?

In this episode, a16z general partner David Ulevitch and Superhuman founder Rahul Vohra discuss how to build products that can turn any user into a power user. The conversation touches on themes from David’s recent talk on products that adopt developer tools, like the command palette and keyboard shortcuts, to improve usability, and Rahul’s talk on how to apply game design principles to product design. They cover how to onboard users to drive virality, when to expand to a second product, and how to use pricing to position a premium product.

Show Podcast Information

As more digital natives have entered the workplace, they have brought with them the expectation that their software should both be a joy to use and allow them to be power users. That is, users who configure and control it to better serves their needs. And often, these digital natives aren’t just aspiring power users, they are also prosumers, who can and will pay for a premium experience. But first generation SaaS products have often struggled to deliver the experience these users crave.

For today’s founders and builders, how do you get the user experience right when a product has to delight your power users, while being something a less savvy user can pick up and learn?

In this episode, a16z general partner David Ulevitch and Superhuman founder Rahul Vohra discuss how to build products that can turn any user into a power user. The conversation touches on themes from David’s recent talk on products that adopt developer tools, like the command palette and keyboard shortcuts, to improve usability, and Rahul’s talk on how to apply game design principles to product design. They cover how to onboard users to drive virality, when to expand to a second product, and how to use pricing to position a premium product.